Zhang Zhigang, Zhu Ying, Wang Zhen, Zhang Ting, Wu Pin, Huang Jian
Department of Gynecology, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, China; Cancer Institute (Key Laboratory of Cancer Prevention & Intervention, National Ministry of Education, Provincial Key Laboratory of Molecular Biology in Medical Sciences), The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, China; Department of Oncology, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, China.
Department of Gynecology, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, China.
Cancer Lett. 2017 May 1;393:1-7. doi: 10.1016/j.canlet.2017.02.008. Epub 2017 Feb 16.
Breast cancer cells secrete chemokines, such as CXCL13, and antigens or express high endothelial venules, attracting B cells to infiltrate into the tumor microenvironment and play a "yin-yang" effect. They not only enhance the anti-tumor immune effect via secreting antibodies and influencing the Fas/FasL, CXCR4/CXCL12 and perforin pathways but they also promote the tumor to form a suppressive milieu by producing immunomodulatory factors and cytokines or using cell-to-cell education to induce the generation of Tregs or myeloid-derived suppressor cells (MDSCs). Currently, most studies on breast cancer tissue have indicated that B cell infiltration could predict better survival and response to therapy, but two studies have reported opposite results. In a 4T1 tumor-bearing BALB/c mice model, B cell-based immunotherapies were administered, but the efficiency was unstable. Herein, we review the "yin-yang" effect of B cells in breast cancer and discuss B cell-based immunotherapy. B cells are complex aggregates, and breast cancer is a heterogeneous disease. Further studies are urgently required to define the B cell subsets and to discover ways to use B cell-based immunotherapy in breast cancer.
乳腺癌细胞分泌趋化因子（如CXCL13）和抗原，或表达高内皮微静脉，吸引B细胞浸润到肿瘤微环境中并发挥“阴阳”效应。它们不仅通过分泌抗体以及影响Fas/FasL、CXCR4/CXCL12和穿孔素途径来增强抗肿瘤免疫效应，还通过产生免疫调节因子和细胞因子或利用细胞间作用诱导调节性T细胞（Tregs）或髓源性抑制细胞（MDSCs）的产生，从而促进肿瘤形成抑制性微环境。目前，大多数关于乳腺癌组织的研究表明，B细胞浸润可预测更好的生存率和对治疗的反应，但有两项研究报告了相反的结果。在一个携带4T1肿瘤的BALB/c小鼠模型中，实施了基于B细胞的免疫疗法，但疗效不稳定。在此，我们综述了B细胞在乳腺癌中的“阴阳”效应，并讨论了基于B细胞的免疫疗法。B细胞是复杂的集合体，而乳腺癌是一种异质性疾病。迫切需要进一步研究来明确B细胞亚群，并找到在乳腺癌中使用基于B细胞的免疫疗法的方法。
